You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Novel Nano-emulsion Immuno-suppressive Adjuvant for Allergy Vaccines

    SBC: EPITOGENESIS INC            Topic: NIAID

    Bronchial asthma is a chronic respiratory disease that can be lethalAsthma is a global health problemAccording to the CDCin USAthere are currentlymillion asthma sufferers and this number is increasingHalf of the asthma patients have at least one hospitalization per yearwith an annual medical cost of $BTraditionallyasthma is treated during flare ups with prescribed inhaled corticosteriodsIn recent ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. TOPIC 394- A VERSATILE RADIATION-TRIGGERED PHOSPHOR PLATFORM FOR LOCALIZED ANTI-CANCER THERAPY

    SBC: PACT & HEALTH LLC            Topic: NCI

    The goal of this project is to fabricate a novel nanoscintillator photosensitizer complex for X ray excited photodynamic therapyXPDTHereina low dose of X raysltGyis used to excite scintillating nanoparticleswhich downconvert ionizing radiation to UV vis lightPhotosensitizers loaded onto the nanoscintillator complex absorb this UV vis emission and generate cytotoxic reactive oxygen speciesROSin the ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. TOPIC 366: I-PARTS INTEGRATED PLATFORM FOR ANTI-CANCER RADIATION THERAPEUTICS SCREENING

    SBC: PACT & HEALTH LLC            Topic: NCI

    Tumor Irradiation during cancer treatment induces clonogenic death that can be best assessed by colony forming assaysThese colony forming assays are laborious and never utilized in high throughput screeningHTSformatsWe propose to develop anintegrated platform for HTS clonogenic survival assayfor cancer drug screening as well as radiation effect modulation screeningNamedI PARTSIntegrated platform f ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Measuring toxicant effects on cellular function in a microarray format

    SBC: CIENCIA INC            Topic: 113

    Project Summary/Abstract – The EPA maintains a Toxics Release Inventory of andgt;650 toxic chemicals that are disposed or released from andgt;20,000 industrial sites in the United States, while HHS and USDA maintain a list of over 60 select agents and toxicants that pose a severe risk to human, animal, and plant health. These compounds represent only a fraction of the known and unknown environme ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  5. A novel vaccine against mosquito-borne Zika virus based on mosquito salivary gland protein AgBR1

    SBC: L2 DIAGNOSTICS LLC            Topic: NIAID

    PROJECT SUMMARYZika virus, an emerging flavivirus, is associated with severe clinical outcomes, including Guillain-Barré syndrome and birth defects. Transmission of Zika virus is primarily mosquito- borne. Mosquito salivary proteins are known to enhance infectivity and pathogenesis in Zika, dengue and West Nile viruses by modulating immune responses. This proposal seeks to develop a novel vaccine ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Small Molecule Apelin Receptor agonists for teh treatment of Heart Failure in PAH

    SBC: VASCUMAB LLC            Topic: NHLBI

    SUMMARY The apelin receptorAPLNRagonist program project is seeking to discover an orally active small molecule drug to preserve and improve the heart s right ventricularRVfunction in patients suffering from pulmonary arterial hypertensionPAHa devastating disease with high morbidity and mortalityThere is compelling evidence that RV function is a major determinant of clinical outcomes in PAH patient ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Development of tumor-targeted PARP inhibitors for the treatment of solid cancers

    SBC: Cybrexa, Inc.            Topic: 102

    PROJECT SUMMARY Monotherapy regimens of poly adenosine diphosphateADPribose polymerase inhibitorPARPihave demonstrated clear efficacy in the clinic against metastatic solid tumorswith the greatest activity observed in homologous recombination deficient HRD cancersbut have limited activity against non HRD cancersAs suchthere is great interest in combining PARPiandapos s with other systemic therapie ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. GALC Pharmacological Chaperone Drugs forKrabbe Disease

    SBC: VASCUMAB LLC            Topic: NICHD

    Project Summary We propose to deliver a GALC pharmacological chaperone to restore enzyme activity for the treatment of Krabbe Disease caused by GALC deficiencyKrabbe disease is a rarefatal degenerative disorder which destroys myelin sheath of the nervous systemMost of the casesoccur in infants beforemonths of age and usually death occurs by ageyearsThe later onset patients usually die betweenandye ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Potent oral chitotriosidase-1 inhibitors as a novel therapy for sarcoidosis

    SBC: ONCOARENDI THERAPEUTICS LLC            Topic: NHLBI

    Abstract Sarcoidosis is a systemic disease with large unmet medical needand unknown causecharacterized by the formation of immune granulomas in various organsmainly the lungs and the lymphatic systemAboutof patients develop a chronic or progressive disease necessitating long term treatmentCurrent therapiesincluding the standard of caresystemic corticosteroidsdo not prolong survival and only have l ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Development of A Narrow Spectrum Anti-Tubercular Agent

    SBC: L2 DIAGNOSTICS LLC            Topic: NIAID

    Abstract Complex and lengthy treatment regimens coupled with rising drug resistance underscore the urgent need for new and better drugs to treat tuberculosis (TB) caused by the bacterium Mycobacterium tuberculosis (Mtb). Current treatment regimens for drug resistant TB involve the use of costly, less effective, and toxic drugs that must be continued for up to 24 months. The work proposed here focu ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government